Enanta Pharmaceutica (ENTA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 09/30
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Sales | 15,125 | 18,314 | 14,926 | 16,959 | 14,607 |
| Gross Profit | 15,125 | 18,314 | 14,926 | 16,959 | 14,607 |
| Operating Expenses | 33,511 | 37,207 | 39,453 | 40,502 | 44,461 |
| Operating Income | -18,386 | -18,893 | -24,527 | -23,543 | -29,854 |
| Interest Expense | 2,387 | 1,618 | 1,714 | 1,962 | 2,581 |
| Other Income | 2,105 | 2,285 | 2,292 | 2,799 | 3,249 |
| Pre-tax Income | -18,668 | -18,226 | -23,949 | -22,706 | -29,186 |
| Income Tax | 32 | 29 | -1,305 | -416 | -363 |
| Net Income Continuous | -18,700 | -18,255 | -22,644 | -22,290 | -28,823 |
| Net Income | $-18,700 | $-18,255 | $-22,644 | $-22,290 | $-28,823 |
| EPS Basic Total Ops | -0.88 | -0.85 | -1.06 | -1.05 | -1.36 |
| EPS Basic Continuous Ops | -0.87 | -0.85 | -1.06 | -1.05 | -1.36 |
| EPS Diluted Total Ops | -0.88 | -0.85 | -1.06 | -1.05 | -1.36 |
| EPS Diluted Continuous Ops | -0.87 | -0.85 | -1.06 | -1.05 | -1.36 |
| EPS Diluted Before Non-Recurring Items | -0.87 | -0.85 | -1.06 | -1.05 | -1.36 |
| EBITDA(a) | $-18,060 | $-17,670 | $-22,508 | $-22,022 | $-30,577 |